Orchard Therapeutics — Q2 2023 Earnings Presentation
19 slides from Orchard Therapeutics's earnings presentation, Aug 3, 2023
Slide 1: Orchard Therapeutics: curative potential of HSC gene therapy
We aspire to end the devastation caused by genetic and other severe diseases through the curative potential of HSC gene therapy.
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation and statements made in this presentation contain forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or
Slide 3: Strong Operational Execution in 1H of 2023
Strong Operational Execution in 1H of 2023 Growing Libmeldy Revenue Progressing Universal Newborn Screening Moving OTL-200 Toward U.S. Approval Initiating Pivotal Study for OTL-203 in MPS-IH Expanding into Larger Indications Strategic financing resulted in $68M of new capital, extending cash runway
Slide 4: Orchard's HSC Gene Therapy Offers a Highly Differentiated, Validated Approach
Orchard’s HSC Gene Therapy Offers a Highly Differentiated, Validated Approach with Opportunities for Expansion Validation in Rare Diseases Larger Indications Future Applications OTL-104 NOD2-Crohn’s OTL-105 HAE OTL-204 FTD Regulatory T cells Monoclonal antibody secretion Multiple opportunities for n
Slide 5: HSC Gene Therapy Allows Delivery of Gene-corrected Cells to Multiple Organ Systems
HSC Gene Therapy Allows Delivery of Gene-corrected Cells to Multiple Organ Systems Monocyte / Macrophage T cells B cells NK cells Megakaryocyte Erythrocyte Granulocyte Integration Self-renewal Osteoclasts Microglia Kupffer Cells Intestinal macrophages X-CGD NOD2 Crohn’s MLD MPS FTD BONE INTEST
Slide 6: ASGCT Snapshot: Six Presentations across Five Programs
ASGCT Snapshot: Six Presentations (Three Oral) across Five Programs OTL-203 for MPS-IH: Additional PoC data demonstrated extensive metabolic correction in the skeletal system resulting in normal growth, skeletal remodeling, improved joint function and progressive acquisition of motor skills OTL-201
Slide 7: OTL-200 (MLD): Potential Significant Clinical Benefit for a Devastating Genetic Disease
OTL-200 (MLD): Potential Significant Clinical Benefit for a Devastating Genetic Disease 1. van Rappard DF, Boelens JJ, Wolf NI. Metachromatic leukodystrophy: disease spectrum and approaches for treatment. Best Pract Res Clin Endocrinol Metab 2015; 29: 261–73. Age 5, pre-diagnosis Age 9, advanced dis
Slide 8: OTL-200 (MLD): BLA Submission Completed; Moving Toward Potential Approval in 1H'24
OTL-200 (MLD): BLA Submission Completed; Moving Toward Potential Approval in 1H’24 BLA Submission and Approval Timeline Summary of Recent Regulatory Correspondence with the FDA Nov. 2022 MLD Scientific Workshop held with the FDA by KOLs and treating physicians of the MLD community Feb. 2023 Informal
Slide 9: Building Global Momentum for Libmeldy
Building Global Momentum for Libmeldy Commercial Potential EU Revenue Growth U.S. Launch Prep ROW Expansion Opportunities Newborn screening and disease awareness to drive patient ID Broad access through qualified treatment center (QTC) network Reimbursement through various pathways Commercial Activi
Slide 10: Expanding Reimbursed Access Throughout Europe
Expanding Reimbursed Access Throughout Europe 10 | Secured for all eligible MLD children Reimbursed early access (e.g., France) Cross border (S2) pathway: (e.g., Central & Eastern Europe) Treatment abroad: (e.g., Middle East) Spain Saudi Arabia KEY Current Treatment Center Planned Treatment center S
Slide 11: Implementing Newborn Screening to Identify MLD Patients
Implementing Newborn Screening to Identify MLD Patients Advancing universal newborn screening for MLD Newborn Metabolic Screening Act (SB67) enacted in Illinois, MLD being added to statewide panel Following study data, application for nationwide screening progressing in Germany Continuing to expand
Slide 12: MLD Represents a Significant Annual Global Market Opportunity
MLD Represents a Significant Annual Global Market Opportunity $250.0M $500.0M $1B Incidence of 1:100,0001 U.S. and EU only (using estimate of 90 patients) Incidence of 1:100,0001 Global (using estimate of 200 patients) Incidence of 1:50,0002 Global (using estimate of 400 patients) Potential annual m
Slide 13: Steady Libmeldy Revenue Growth Since Launch
Steady Libmeldy Revenue Growth Since Launch Patients from 6 different countries treated commercially at 4 of 5 qualified centers Reimbursement via access agreements, cross-border and named patient pathways Average vein-to-vein time of 55 days with 100% success in production Company on track for year
Slide 14: Success in MLD Provides Roadmap, Common Infrastructure for Next Programs
Success in MLD Provides Roadmap, Common Infrastructure for Next-in-line Neurometabolic and CNS Programs PLATFORM SYNERGIES Regulatory Manufacturing Distribution Supply Chain Treatment Sites Referral Networks MPS-IH MPS-IIIA Other LSDs GRN-FTD MLD Approved in Europe; BLA submitted to U.S. FDA
Slide 15: OTL-203 (MPS-IH): Moving into a Pivotal Trial in 2H 2023
OTL-203 (MPS-IH): Moving into a Pivotal Trial in 2H 2023 Randomized controlled trial vs. HSCT (standard of care) 40 patients 2-year primary analysis Composite endpoint Up to 6 U.S. / EU sites
Slide 16: Prioritizing Commercial Growth, Pipeline Development and Expense Management
Prioritizing Commercial Growth, Development of Pipeline and Expense Management to Generate Value 29% decrease from 1H’22 to 1H’23 Anticipated year-over-year increase in Libmeldy product sales Ongoing management of operating expenses Annual burn rate expected to continue declining in 2023 vs. 2022
Slide 17: Summary of Q2'23 Financial Results
Summary of Q2’23 Financial Results Three Months Ended June 30 Statement of Operations: 2023 2022 % Change Libmeldy product sales $6.6M $3.2M +111% Strimvelis product sales - $0.6M - Collaboration revenue $0.7M $0.6M +13% Total revenues $7.3M $4.4M +67% Cost of product sales $2.2M $1.1M +95% Research
Slide 18: Executing on Key Corporate Milestones
Executing on Key Corporate Milestones Approximately $155.0M in Cash and Investments as of Q2’23 Supports Runway to mid-2025 Post GT Treatment Advance other preclinical pipeline programs (e.g., OTL-105) and enabling technologies (e.g., HSC Tregs) OTL-200: Completed rolling BLA submission to U.S. FDA
Slide 19: Post GT Treatment Strategic Anchors Represent Breakout Opportunities
Post GT Treatment Strategic Anchors Represent Breakout Opportunities for Orchard All based on a HSC GT scientific and clinical platform Future Potential Regulatory Approvals Leverage success in rare disease Diagnostics and Newborn Screening Develop markets Commercial Model Establish scalable busines